Comparative Pharmacology
Head-to-head clinical analysis: NITRO IV versus NITROGLYCERIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITRO IV versus NITROGLYCERIN.
NITRO IV vs NITROGLYCERIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase cGMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.
Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing cGMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.
Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.
Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.
None Documented
Clinical Note
moderateNitroglycerin + Etacrynic acid
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid."
Clinical Note
moderateNitroglycerin + Bumetanide
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bumetanide."
Clinical Note
moderateNitroglycerin + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydrochlorothiazide."
Clinical Note
moderateNone Documented
1-4 minutes (rapidly cleared from blood); terminal half-life ~2-3 minutes due to rapid biotransformation in RBCs and vascular tissue.
Terminal half-life: 1–4 minutes for the parent compound; clinical effects dissipate within the same time frame, correlating with rapid metabolism.
Renal (minimal, <1% unchanged) and hepatic metabolism; metabolites excreted renally.
Metabolized extensively by hepatic glutathione-organic nitrate reductase and other non-specific esterases; renal excretion of metabolites accounts for approximately 50%, with fecal elimination of about 20-30%. Less than 1% of unchanged drug is excreted renally.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator
Nitroglycerin + Indapamide
"The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Indapamide."